CureVac (NASDAQ:CVAC – Get Free Report) and Savara (NASDAQ:SVRA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.
Profitability
This table compares CureVac and Savara’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CureVac | -463.49% | -49.22% | -33.85% |
| Savara | N/A | -51.95% | -40.45% |
Valuation & Earnings
This table compares CureVac and Savara’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CureVac | $58.18 million | 12.58 | -$281.58 million | ($1.33) | -2.46 |
| Savara | N/A | N/A | -$54.70 million | ($0.37) | -13.70 |
Analyst Ratings
This is a breakdown of current ratings and target prices for CureVac and Savara, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CureVac | 1 | 3 | 1 | 0 | 2.00 |
| Savara | 0 | 0 | 6 | 0 | 3.00 |
CureVac currently has a consensus price target of $10.00, suggesting a potential upside of 205.81%. Savara has a consensus price target of $11.00, suggesting a potential upside of 116.96%. Given CureVac’s higher possible upside, equities analysts clearly believe CureVac is more favorable than Savara.
Insider and Institutional Ownership
17.3% of CureVac shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 5.1% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility & Risk
CureVac has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500. Comparatively, Savara has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
Summary
Savara beats CureVac on 7 of the 13 factors compared between the two stocks.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
